{"id":"NCT02002832","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","briefTitle":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","officialTitle":"A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2015-04","completion":"2015-11","firstPosted":"2013-12-06","resultsPosted":"2019-04-01","lastUpdate":"2019-11-15"},"enrollment":388,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Lurasidone tablets","otherNames":["LATUDA"]},{"type":"DRUG","name":"Risperidone tablets","otherNames":[]}],"arms":[{"label":"Lurasidone group","type":"EXPERIMENTAL"},{"label":"Risperidone group","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.","primaryOutcome":{"measure":"Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.","timeFrame":"From baseline to Week 6(day 42).","effectByArm":[{"arm":"Lurasidone Group","deltaMin":-31.2,"sd":null},{"arm":"Risperidone Group","deltaMin":-34.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":194},"commonTop":["Extrapyramidal disorder","Consitpation","Nasopharyngitis","Akathisia","Insomnia"]}}